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One of the primary drugs used in treatment of acute lymphoblastic leukemia is L-
asparaginase (ASNase), which despite its therapeutic efficacy, faces challenges often 
faced in protein drug treatment: the immunogenicity and short half-life of the drug. In 
order to overcome these major challenges, the red blood cell (RBC) encapsulation 
method has been employed to prevent degradation by serum proteases and elimination by 
reticuloendothelial system, thereby increasing circulation half-life of the protein drug. 
However, the encapsulation methods used thus far, such as hypotonic dialysis/resealing 
and electroporation, showed compromise in the oxygen transport function and structural 
integrity of RBCs.  
Herein we introduce a novel RBC encapsulation method that involves low 
molecular weight protamine (LMWP), a protein transduction domain (PTD) peptide. 
Protein drug was first conjugated to LMWP via disulfide bond and the cell penetrating 
property of LMWP allowed encapsulation of protein drug into RBCs as verified by the 
confocal microscopy images. The optimal encapsulation condition was determined to be 
37 °C for 30 minutes. Hematological parameters as well as SEM and osmotic fragility 
curve of LMWP-ASNase encapsulated RBCs showed that the structural integrity was 
maintained while Hill coefficients and pO50 values indicated oxygen transport 
functionality was maintained. LMWP-mediated encapsulation method considerably 
increased the circulating half-life of ASNase compared to that of the hypo-osmotic 
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rupture/resealing method and improved the survival time of tumor-bearing mice by 44% 
compared to the saline control group.  
Based on these data, novel method for encapsulating protein drugs into intact and 





Acute lymphoblastic leukemia (ALL) 
Acute lymphoblastic leukemia (ALL) is cancer of the white blood cells, the cells that 
normally fight infections. As the number of lymphocytes increase in the blood and bone 
marrow, there is also less room for healthy white blood cells, red blood cells, and 
platelets. As a consequence ALL patients often suffer infections, anemia, and easy 
bleeding. Almost 4000 cases of ALL are diagnosed annually in the United States alone, 
approximately two thirds of which are in adolescent children, making ALL the most 
common cancer in this age group. Indeed, ALL represents 23% of the cancer diagnoses 
among children younger than 15 years of age, occurring at an annual rate of 30 to 40 per 
million1. While a cure rate of ~80% was estimated for childhood ALL, the experience 
with adult ALL was far less rewarding, as the reported cure rate seldom exceeded 40%2. 
 
L-Asparaginase 
One of the primary drugs used in the treatment of ALL is L-asparaginase (ASNase). 
ASNase was first discovered in 1953 by Kidd in guinea pig serum3 and has been in 
clinical use since 19674. ASNase is an enzyme that hydrolyzes amino acid L-asparagine 
(ASN) to L-aspartic acid (ASP) and ammonia. Most human tissues can self-synthesize 
ASN from L-glutamine by the action of asparagine synthetase (AS). Certain neoplastic 
tissues, including ALL cells, however, express significantly lower levels of AS and thus 
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have to rely solely on extracellular source of ASN to maintain protein synthesis5. 
Systemic depletion of ASN by ASNase would therefore impair protein biosynthesis in 
these cells, leading to their deaths through cellular dysfunction6. 
However, ASNase therapy is not without problems. Aside from hypersensitivity, 
which will be addressed in the next section, the use of ASNase can result in liver 
dysfunction. The elevated transaminase, abnormal bilirubin and alkaline phosphatase 
levels, and depression in albumin and lipoprotein levels have been observed.7 Other 
toxicities of ASNase include coagulation abnormalities, pancreatitis, cerebral 
dysfunction, parotitis, and immune suppression. 
ASNase formulations currently in use originate from two bacterial sources: 
Escherichia coli and Erwinia chrysanthemi. The active form of enzyme is tetrameric with 
each monomer containing an active site and has an overall molecular weight of 133-140 
kDa. The specific activity of purified ASNase ranges between 300-400 umole of 
substrate/min/mg of protein. The isoelectric point lies between pH 4.5-5.5 for the E.coli 
enzyme and 8.6 for Erwinia enzyme.8 The Km is approximately 1 x 10-5 M.9 ASNase is 
not adsorbed from the GI track and thus, in clinical use, is normally administered 
intravenously or intramuscularly. 
 
Problems with Protein Drug Delivery and Remedies 
As with most protein drugs, the clinical application of ASNase faces two major 
obstacles. First, due to the bacterial origin of ASNase its clinical use is associated with a 
high incidence of hypersensitivity. ASNase can trigger significant immunological 
consequences that include activation of B-lymphocytes and production of antibodies 
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causing severe anaphylactic reactions. When a patient has a reaction, the route of 
administration, form or source of drug is changed. The reaction rate with intravenous (iv) 
administration of the free form is very high. For this reason the free enzyme is almost 
always given by an intramuscular (im) or subcutaneous (sc) route. Most reactions occur 
within one to several hours after administration and include signs and symptoms typical 
of anaphylaxis, sometimes including death. 
Secondly, as with most protein drugs, ASNase is susceptible to degradation by 
serum proteases and elimination by the reticuloendothelial system (RES). The plasma 
half-life of ASNase is estimated to be in the range of 8-30 hrs.10 This rapid clearance 
necessitates frequent injection of large doses, further elevating the possibility of inducing 
immunological responses. 
To overcome such problems of short circulating half-life and immunogenicity, 
various remedies have been attempted. The most successful or commonly employed 
methods to-date includes: attaching hydrophilic polyethylene glycol (PEG) to enzyme 
drug, or encapsulating drug into soluble, synthetic (e.g. polymers) or natural (e.g. 
liposomes, cells) carriers. Attachment of PEG chains to enzyme drug increases its mass 
as well as shields the enzyme from proteolytic degradation, improving pharmacokinetics 
of the drug.11  
Indeed, the PEG-modified ASNase, with a trademark name of pegaspargase, has 
been successfully developed during the 1970s, with its first clinical trial in the 1980s.  
Clinical results showed that attachment of PEG molecule increased the half-life of 
ASNase from 26 hrs to 12 -15 days13. In addition, because of the assistance of PEG in 
alleviating detection by the host immune system, this new form of ASNase was better 
 4 
tolerated than the free form, especially when given intramuscularly.  Hence, pegaspargase 
has been specifically indicated for treating ALL patients who are sensitive to native 
ASNase.  According to a review of clinical data, in re-induction therapy for patients who 
were hypersensitive to E. coli-derived ASNase, pegaspargase was able to reduce the 
frequency of drug administration from 6-9 times to 1-2 times per therapy.  Nevertheless, 
pegaspargase has not yet been proven to be superior to E. coli ASNase for the first 
remission of ALL.  Most critically, pegaspargase failed to completely abort the 
anaphylactic responses in patients who are hypersensitive to ASNase therapy. 
 
Red Blood Cells (RBCs) as Drug Carrier 
Among all carriers employed for ASNase encapsulation, the use of RBCs (red blood 
cells; RBCs) as the drug carrier appears to be most appealing, simply because the RBCs 
would not only protect the loaded protein drug from proteolytic degradation but also 
prevent detection of the drug by the host immune system.  Furthermore, RBCs are 
completely biodegradable without generation of toxic products, and they are also 
biocompatible, particularly when autologous RBCs are used.  In addition, RBCs are the 
most abundant cells of the human body (5.4x106 and 4.8x106 RBCs/mL in men and 
women, respectively), therefore giving an affordable source of supply for use in drug 
encapsulation.  Moreover, the biconcave disk shape of RBCs endows them with the 
highest surface to volume ratio (1.9x104cm/g) usable for drug encapsulation.14 Most 
critically, RBCs possess a lifespan in circulation of approximately 120 days, which is 
significantly longer than any of the currently existing drug carriers.  A detailed discussion 
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of the benefits of utilizing RBCs as the drug carrier can be found in a review article 
authored by Hamidi and Tajerzadeh.15  
 
RBC Loading Methods 
A variety of methods have already been developed to entrap protein drugs into 
RBCs.  The most adapted techniques thus far include drug (e.g. primaquine, 
hydrocortisone, etc.)-induced endocytosis16, electroporation17, and hypo-osmotic-based 
pre-swelling18, rupture/resealing19, 20 or dialysis21. Using these methods to create 
sufficiently large pores or perturbations on the cell membrane, a number of the 
impermeable protein drugs including ASNase, erythropoietin, acetaldyhyde 
dehydrogenase, and alcohol dehydrogenase have been successfully loaded into RBCs. 
Despite reasonable success, all of these methods are still beset by a host of 
shortcomings.  The most crucial drawbacks come from two aspects following RBC 
processing.  First, these techniques all require the application of a chemical (drug-induced 
endocytosis), electrical (electroporation), or mechanical (osmotic dialysis) force to the 
RBC membrane to create sufficiently large pores for the protein drug to diffuse through.  
Such disruption of the cell membrane often leads to partial, but irreversible, deterioration 
of the structural integrity and morphology of the RBC. A significant alteration of the 
RBC morphology from the native discocyte form (i.e. normal RBCs with a small area of 
central pallor and biconcave disc shape) to stomatocyte (i.e. abnormal RBCs with oval or 
rectangular area of central pallor) following treatment by electroporation22 and hypo-
osmosis23 was observed (see Figure 1).  Consequently, these processed RBCs will be 
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recognized by the phagocytic system as foreign entities, rendering their rapid destruction 
and clearance by the host immune system. 
The second issue is that RBCs processed by any of the existing encapsulation 
methods, regardless of whether it is electroporation or hypotonic dialysis, would 
inevitably result in a loss of important cellular constituents, such as hemoglobin and 
cytoskeleton, from the cells.  This is because all of these methods rely on a pore-opening 
and a resealing step, both of which involve a dialysis procedure.20, 24 Thus far, the largest 
protein encapsulated in RBCs by using such methods was alcohol oxidase from Pichea 
pastoria,25 which had a molecular weight (675 kDa) that was 10-fold larger than that of 
hemoglobin (65 KDa); the major constituent of an RBC.  Since dialysis is an equilibrium 
process and with such large pores being created on the cell membrane, in theory and 
practice, it is inevitable that a certain portion of the cytosolic constituents including 
hemoglobin, glutathione, and cytoskeleton would be leaked out of the RBC.  Indeed, loss 
of hemoglobin was clearly observed in RBCs treated with the hypotonic dialysis, and 
electroporation method, as evidenced by a decrease in mean corpuscular hemoglobin 
(MCH) (see Table 1) and presence of a pinkish color after resealing.20  
It should be noted that aside from the principal activity of oxygen transport, RBCs 
also carry out other important biological functions, such as energy (ATP)-involved 
metabolic processes and scavenging of oxidative stressors.26  Hence, a loss of 
hemoglobin would not only impair the oxygen transport function of RBCs, but also affect 
their ability to manage oxidative stress.  Similarly, a loss of cytoskeleton from the RBCs 
would compromise it with a much weakened structural integrity, rendering it prone to 
destruction or recognition by the phagocytic system. Structural integrity of RBCs can be 
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evaluated by examining osmotic fragility of RBCs. As evidenced by osmotic fragility 
test, the RBCs that underwent hypo-osmotic dialysis procedure showed hemolysis at all 
osmotic pressures indicating existence of various cell populations, with the majority of 
hemolysis occurring at lower values of the osmotic fragility curve. On the other hand, 
normal RBCs displayed “sudden” hemolysis resulting in an osmotic fragility curve with a 
sigmoidal profile.27  
It is important to point out that in order to inherit the benefits of RBCs as a natural 
and long-lasting drug carrier, it is absolutely essential to retain both the structural and 
functional integrity of the cell.  Yet, all of the existing RBC encapsulation methods fail to 
recognize this critical point.  Therefore, there is a need of a method that would permit 
encapsulation of therapeutically active protein drugs into fully functional RBCs. 
 
PTD-Mediated Drug Loading 
Recently, a family of small but extraordinarily potent membrane permeable peptides, 
classified as “PTD” (protein transduction domain) peptides that include TAT28, ANTP29, 
VP2230, poly (arginine) peptides31, and the non-toxic, naturally occurring low molecular 
weight protamine (LMWP) developed in our laboratory32, 33 have been discovered. Both 
in vitro and in vivo studies revealed that, by covalently linking PTD to almost any type of 
molecular species including proteins (MW > 150 kDa; more than 60 different proteins 
have already been tested34), nano-carriers35, 36, and liposomes37, PTD was able to ferry the 
attached species across cell membranes.  
More specifically, when a fusion protein of TAT, the most widely studied PTD, and 
β-galactosidase was injected into mice by intraperitoneal injection, β-galactosidase 
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activity was observed in every organ and tissue, including kidney, heart, and even brain28. 
This finding suggests that intracellular protein uptake mediated by the PTD peptide is not 
receptor- or transporter-dependent as different types of cells cannot possess the same 
types of receptors and transporters. In addition, PTD-mediated cell internalization did not 
induce perturbation or alteration of the cell membrane.38 Based on this conclusion, in 
theory all cell types, including RBCs, should be transducible and PTD peptides could 
potentially be applied as a powerful tool to achieve non-invasive encapsulation of 
biologically active protein therapeutics into intact and fully functional cells. 
 
LMWP 
In order to encapsulate the therapeutic protein ASNase into RBCs, we propose the 
use of LMWP, one of the PTD peptides. LMWP is an arginine-rich peptide created by 
enzymatic digestion of protamine with thermolysin which results in 5 different fractions 
designated TDSP (thermolysin-digested segmented protamine). The fraction of the 
choice, TDSP-5, and now termed LMWP, has the sequence of VSRRRRRRGGRRRR 
and has molecular weight of 1880. Initially developed as a non-toxic antagonist to 
heparin and low molecular weight heparin (LMWH), the LMWP sequence bears close 
similarity to many of the arginine-rich PTD peptides, such as TAT, which has amino acid 
sequence of GRKKRRQRRRPPQ. When HeLa cells were incubated with LMWP labeled 
with FITC (fluorescein isothiocyanate), a commonly used fluorescence tag, LMWP 
displayed cellular uptake comparable to that of TAT44. 
LMWP has several unmatched advantages over other existing PTDS. First, unlike 
other PTDs that rely solely on chemical synthesis for their production, LMWP can be 
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manufactured in mass quantities using enzymatic hydrolysis and a single step purification 
system.  Second, unlike most other PTDs that are derived from viral sources and, thus, 
present health concerns, LMWP is obtained from digestion of native protamine, a FDA 
approved clinical drug.  Third, unlike all existing PTDs, the toxicology profile of LMWP 
has already been thoroughly established; the LMWP peptide is neither toxic nor 
immunogenic33, 39, 40, 41. Last but not least, since LMWP possesses only one single -NH2 
group at the N-terminus, its conjugation to a protein drug can be precisely regulated and 
easily carried out using our established N-succinimidyl-3-(2-pyridyldithio) propionate 
(SPDP) activation method.42 
 
Research Objectives 
In this thesis dissertation, PTD-mediated RBC encapsulation of ASNase for potential 
treatment of acute lymphoblastic leukemia is investigated. The main goals of the project 
were to: 1) successfully produce LMWP-conjugated ASNase with sufficient retention of 
enzyme activity; 2) verify encapsulation of LMWP-ASNase conjugate in RBCs, optimize 
the RBC loading process, and determine whether PTD-mediated loading procedure alters 
functionality and/or physical properties of RBCs; and finally 3) determine whether 
encapsulation of ASNase in RBCs will extend circulating half-life of ASNase as well as 






Loading Method Electroporation Hypo-osmotic Dialysis 
Species Mouse Human 
Parameters Native RBCs Loaded RBCs Native RBCs Loaded RBCs 
MCV (fl) 52.1 ± 0.5 71.9 ± 0.9 94 ± 2 79 ± 1 
MCH (pg) 17.5 ± 0.4 15.1 ± 0.9 32.0 ± 0.8 25.6 ± 0.9 
MCHC (g/dl) 33.6 ± 0.7 21.1 ± 1.4 34.2 ± 1.1 33.1 ± 0.7 
n 11 4 16 16 
 
Table 1. (a) Hematological parameters for mouse RBCs encapsulated with alcohol 
dehydrogenase loaded by electroporation under optimal experimental conditions (420 V, 
four pulses of 1ms every 15 min. at 37°C; resealing for 1 hr at 37°C; n = number of 
experiments (means ± S.E.M.)) and (b) human RBCs encapsulated with xxx by dialysis 
bag method (45 min). The RBC suspensions were adjusted to 70% haematocrit and 4 








Figure 1. Scanning electron micrographs of human RBCs before (A) and after (B) 
undergoing hypotonic preswelling method; mouse RBCs before (C) and after (D) 









Figure 2. Schematic of LMWP-mediated ASNase loading into intact RBCs. 
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Chapter 2 
LMWP-ASNase: Conjugation and Characterization 
Introduction 
Despite various methods used to encapsulate protein drugs into RBCs the circulating 
half-life as well as the structural and morphological integrity of RBCs show room for 
improvement. To this regard we proposed use of PTD-, more specifically LMWP-
mediated RBC encapsulation to resolve these issues. The bioconjugation of LMWP to 
ASNase was then necessary. Another consideration was the type of linkage used between 
LMWP and ASNase. In order to avoid the possibility of LMWP-mediated leaching of 
ASNase out of the RBCs use of a disulfide bond was proposed. These bonds have been 
known to break under reducing environment, in this case, cytosol of RBCs, and will 
allow ASNase to remain inside upon encapsulation. 
Conjugation of LMWP to ASNase via a disulfide bridge can be accomplished in 
three steps (see Figure 3) by use of two key reagents: Traut’s reagent (also known as 2-
iminiothiolane) and N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP). 
Traut’s reagent, also known as 2-iminiothiolane, is a thiolating reagent used in the 
preparation of disulfide and thioether linked conjugates. It has a preference for primary 
amino groups and reacts at pH 7 - 10 to give amidine compounds that contain free 
sulhydryl groups. The amidine linkage preserves the original primary amine positive 
charge.43 SPDP is a heterobifunctional cleavable cross-linking agent. It contains one 
amine reactive N-hydroxysuccinimide (NHS) residue and one sulfhydryl reactive pyridyl 
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disulfide residue. The NHS-ester cross-linking reactions should be performed in buffers 
such as phosphate, bicarbonate/carbonate and borate buffers that do not contain primary 
amines. The optimum pH for this reaction is between 7 and 8. 
In the first step, ASNase is reacted with Traut’s reagent to create a free thiol group. 
In the second reaction, a 2-pyridyl-disulfide group is introduced into LMWP by the 
reaction between the primary amine group of the peptide and the N-hydroxysuccinimide 
ester side of SPDP. Finally sulfhydryl exchange occurs between the thiol group of 
ASNase and the 2-pyridyl-disulfide group of LMWP. Pyridine-2-thione is released and 
its concentration can be determined by measuring the absorbance at 343 nm. 
One of the important aspects of chemical modification of ASNase to keep in mind is 
its enzyme activity. Chemical modification of an enzyme drug has been known to alter its 
activity depending on the site of modification. When conjugating LMWP to ASNase it is 
necessary to control for the degree of conjugation while retaining sufficient specific 
enzyme activity to preserve its therapeutic effect. 
For the RBC-encapsulated ASNase to function properly in vivo, it is crucial for the 
enzyme to maintain its therapeutic activity during the encapsulation process as well as in 
circulation. In this chapter we describe: first, the chemical reaction and purification steps 
undertaken to conjugate LMWP to ASNase by a disulfide bond; second, the 
characterization of the final product MALDI-TOF MS method, followed by effect of the 
conjugation process on specific enzyme activity of ASNase; and last, the storage stability 
of the final product. 
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Materials and Methods 
LMWP-ASNase Preparation 
Low molecular weight protamine (LMWP) was produced in our lab according to the 
method previously described44. To activate LMWP, a five molar excess of SPDP (Sigma-
Aldrich, St. Louis, MO) was dissolved in DMSO and added drop-wise to LMWP (5 
mg/mL) dissolved in phosphate buffer (0.1 M, with 1mM EDTA, pH 8.0), and the 
mixture reacted at room temperature for 2 hours. Activated LMWP detectable at 214 nm 
was purified by HPLC on a heparin affinity column (Buffer A: 50 mM phosphate, 1 mM 
EDTA, pH 7.5; Buffer B: 50 mM phosphate, 1 mM EDTA, 2 M NaCl, pH 7.5) followed 
by concentration using an ultrafiltration cell with a 500 MWCO membrane (Spectrum 
Laboratories, Inc. Rancho Dominguez, CA). Degree of activation was determined by 
monitoring pyridine-2-thione generation, detectable at 343 nm, upon addition of DTT 
(dithiothreitol) to purified LMWP-PDP. 
ASNase (Elspar, Ovation Pharmaceuticals, Inc., Deerfield, IL) was dissolved in 0.1 
M HEPES buffer containing 5mM EDTA and reacted with a 10 fold excess (per 
monomer) Traut’s reagent (Sigma-Aldrich, St. Louis, MO) at room temperature for 1 
hour and purified by HPLC using two desalting columns in series (HiTrap, GE 
Healthcare, Piscataway, NJ; isocratic, Buffer A: 50 mM phosphate, 1 mM EDTA, pH 
7.5). Monitoring the fractions at wavelength of 254 nm allowed detection of both 
ASNase-SH and unreacted Traut’s reagent. Degree of thiolation was determined using 
Ellman’s Reagent (Sigma-Aldrich, St. Louis, MO), which reacts with free sulfhydryl 
groups. Finally, to the thiolated ASNase, 5 fold excess activated LMWP (relative to thiol) 
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was added to react at room temperature for 2 hours and the final product was purified by 
HPLC on a heparin affinity column (Buffer A: 50 mM phosphate, 1 mM EDTA, pH 7.5; 
Buffer B: 50 mM phosphate, 1 mM EDTA, 2 M NaCl, pH 7.5) and concentrated using an 
ultrafiltration cell with a 10,000 MWCO membrane (Spectrum Laboratories, Inc.). 
MALDI-TOF Analysis 
MALDI-TOF-MS method was used to determine actual degree of LMWP 
conjugation to each ASNase monomer. MALDI-TOF-MS analysis was run in linear 
mode on Waters Tofspec-2E, calibrated with bovine serum albumin. The data was 
acquired and processed using Masslynx 3.5 software. Sinnapinic acid was used as matrix.  
ASNase Activity Measurement 
ASNase activity was determined by direct nesslerization of produced ammonia.  In 
this reaction, ASNase is incubated with its substrate ASN at 37 °C, pH 8.6, for a 
specified time and generated ammonia is captured by Nessler’s reagent. More 
specifically, for each measurement, a microcentrifuge tube containing 850 uL of 60 mM 
ASN in Tris-HCl (50mM, pH 8.6) and 100 uL Tris-HCl (50mM, pH 8.6) was pre-
incubated at 37 °C for 5 minutes to achieve temperature equilibration. To this solution, 
50 uL of LMWP-ASNase or native ASNase solution was added and incubated for 10 
minutes before quenching the reaction with 100 uL of trichloroacetic acid (1.5 N, Sigma-
Aldrich, St. Louis, MO). The reaction mixture was centrifuged at 15000 rpm for 3 
minutes and 50 uL of the supernatant was added to a microcentrifuge tube containing 700 
uL of DI H2O and 100 uL of Nessler’s Reagent (Sigma-Aldrich, St. Louis, MO). The 
resulting solution was incubated for 15 minutes at room temperature before measuring 
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absorbance at 480 nm. Enzymatic activity unit is defined as µmol ammonia produced per 
minute.  Specific activity of native ASNase ranged from 206 to 259 units/mg of protein. 
LMWP-ASNase Thermal Stability 
Solution of LMWP-ASNase at a concentration of 50 ug/mL was prepared. Three 
aliquots of this solution was stored at 4°C and another three at 37°C. At specific time 
points, 50 µL from each vial were collected and measured for enzyme activity by direct 
nesslerization. 
LMWP-ASNase Storage Stability 
Two hundred microliter aliquots of LMWP conjugated- or native- ASNase solutions 
(~1 mg/mL each) were prepared in reversed Hank’s balanced salt solution (R-HBSS; KCl 
10.18 g/L, KH2PO4 0.1 g/L, NaHCO3 1.273 g/L, NaCl 0.316 g/L, Na2HPO4 0.08 g/L, 
glucose 2.0 g/L; pH adjusted to 7.4 with H3PO4, 85 % w/v)45 and stored at 4, -20, and -80 
°C. At specified time points, one vial was removed from each storage location and 
diluted to 50 ug/mL before analysis by direct nesslerization. 
 
Results and Discussion 
LMWP-ASNase Conjugation and Characterization 
With the use of heterobifunctional linker SPDP and Traut’s reagent, LMWP-ASNase 
linked by disulfide bond was synthesized. The SPDP activated LMWP is easily separated 
from the biproducts and excess SPDP with use of a heparin affinity column, as seen by 
FPLC chromatogram in Figure 4. With Traut’s reagent and ASNase both absorbing at 
254 nm, the ASNase and excess Traut’s reagent fractions were sufficiently separated 
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when two desalting columns were used in series with the thiolated ASNase eluting at 
approximately 2.6 minutes (Figure 5). 
LMWP-ASNase conjugation products were purified by FPLC on a heparin affinity 
column. The elution profile shown in chromatogram (Figure 6) in conjunction with 
MALDI-TOF analysis of separated fractions verified that ASNase fractions eluted in 
order of increasing degree of LMWP conjugation, positive charge from LMWP 
contributing to increased affinity to heparin. 
The initial RBC loading experiment indicated that the amount of ASNase 
encapsulated was higher for the fraction with greater degree of LMWP-modification. 
When the ASNase fractions eluting at 0.6 M and 1.2 M NaCl were compared for RBC 
encapsulation, the fraction at 1.2 M showed significantly higher loading as seen in Figure 
7. The MALDI-TOF MS analysis also verified that the fraction at 1.2 M had a higher 
degree of LMWP conjugation per ASNase tetramer than the fraction at 0.6 M (data not 
shown). 
With the base peaks at m/z 34526, m/z 36639, m/z 38761, and m/z 40828 
corresponding to ASNase monomer, monomer with one LMWP, two LMWPs, and three 
LMWPs, respectively, MALDI-TOF-MS results indicated that up to 3 LMWP peptides 
could be conjugated to each ASNase monomer, or up to 12 LMWP peptides per ASNase 
tetramer, the active form. At the end of conjugation and purification process, 55 - 60 % of 
the original specific enzyme activity was retained. 
LMWP-ASNase was found to have Vmax and KM values of 627.7 and 0.031, 
respectively, while corresponding values for native ASNase were 339.8 and 0.016. 
Although these Michael-Menton kinetic parameters differed for two ASNase forms, their 
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catalytic efficiency, the ratio between Vmax and KM, was comparable at 2.12 x 104 and 
2.02 x 104, indicating that in terms of depleting systemic ASN level the two forms should 
be  on par with each other. 
In order to verify that the LMWP-ASNase conjugate will remain stable/active during 
storage before the loading process, storage stability test was performed at 4, -20, and -80 
°C. Results indicated that while storage at 4 °C results in loss of slightly over 10 % of 
original activity over 25 days, the enzyme activity is well preserved when stored frozen at 
-20 and -80 °C shown in Figure 9. 
One of the requirements for the RBC loading process is that the protein drug of 
interest remains active during the loading procedure and also during circulation in vivo. 
To test this issue, the conjugate stability at 4 and 37 °C was tested. While a slight 
decrease in enzyme activity was observed for LMWP-ASNase stored at 4 °C, the enzyme 













Figure 3. Schematic of LMWP to ASNase conjugation procedure. A disulfide bridge 
between ASNase and LMWP is created by activation of LMWP with SPDP and 






























Figure 5. Purification of ASNase thiolation with Traut's reagent reaction by FPLC 
with two desalting columns in series. (Isocratic; Buffer A: 50 mM phosphate, 1mM 







Figure 6. FPLC chromatogram of LMWP-ASNase conjugation mixture. (Buffer A: 
50 mM phosphate, 1 mM EDTA, pH 7.5; Buffer B: 50 mM phosphate, 1 mM EDTA, 











Figure 7. Fraction eluting at higher salt concentration shows higher loading 














Figure 8. MALDI-TOF mass spectra of LMWP-ASNase conjugates prepared by 
coupling SPDP activated LMWP to the thiolated ASNase. Up to three LMWP 



















Paramter Native ASNase LMWP-ASNase 
Vmax 339.8 627.7 
KM 0.016 0.031 
Vmax/KM (catalytic efficiency) 2.12 x 104 2.02 x 104 
 
 











Figure 9. Storage stability comparison of LMWP-ASNase to native ASNase. Two 
forms of ASNase were stored at 4 (A), -20 (B), and -80 (C) °C and enzyme activity 
was measured at specified time points using direct nesslerization method (: 











Figure 10. LMWP-ASNase stability at 4 and 37 °C. LMWP-ASNase conjugate was 
incubated at specified temperatures and an aliquot was removed at each time point 
to determine enzyme activity by direct nesslerization.
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Chapter 3 
PTD-Mediated RBC Encapsulation of L-Asparaginase 
Introduction 
Active research on use of RBC as a drug carrier has been going on since the 1980s. 
However, the encapsulation methods used with these therapeutic protein drugs was 
shown to compromise structural and functional integrity of RBCs. In order to take most 
advantage of the long life span of RBCs, it is necessary to preserve its major function as 
an oxygen carrier as well as its morphology and structural integrity. With the use of 
LMWP as a PTD peptide, these issues can be overcome, extending the circulating life 
span of RBCs, which in, turn will extend the circulating half-life of encapsulated protein 
drug. 
In this chapter we will show LMWP-mediated cell uptake of protein into RBCs 
followed by steps taken to optimize LMWP-mediated RBC loading process. In addition, 
we demonstrate that these enzyme-encapsulated RBCs retain their natural morphology 
and their major function as oxygen carriers. 
 
Materials and Methods 
Blood Collection 
Mice were anesthetized with ketamine/xylazine and blood collected by cardiac 
puncture was immediately transferred into microcentrifuge tube containing EDTA as an 
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anticoagulant. Blood was centrifuged to remove serum and separated RBCs were washed 
three times with R-HBSS before use. 
RBC Uptake of Fluorescence-Labeled LMWP-Ovalbumin Conjugates 
Commercial Alexa Fluor-488-labeled ovalbumin (Invitrogen, Carlsbad, CA) was 
activated using SPDP and then conjugated to LMWP. For uptake experiments, fresh 
sheep RBCs (MP Biomedicals, Solon, OH) were suspended in Hank's balanced salt 
solution (HBSS) at a density of 5 x 108 cells/ml, and were then incubated with a 0.5 
mg/ml solution of the LMWP-ovalbumin conjugates for 30 min at room temperature 
under gentle shaking. RBCs were then washed with HBSS, fixed with 2% 
paraformaldehyde for 20 min, mounted on glass chamber slides, and uptake was 
examined using a confocal laser scanning microscope (LSM 510 META, Carl Zeiss, 
Jena, Germany). 
Effect of Temperature on Loading 
RBCs were incubated in LMWP-ASNase in R-HBSS (20 uL PCV RBC/ 75 IU 
ASNase/ mL) for 1 hour at 4°C or 37°C. RBCs were then washed and lysed to measure 
for enzyme activity. 
Loading Kinetics Experiment 
Washed RBCs were added to R-HBSS containing LMWP conjugated-, free-, or no 
ASNase and incubated in shaking water bath at 37 °C. An aliquot of 1 mL was removed 
from each vial at previously specified time points, centrifuged, washed 3 times with R-
HBSS. Washed RBCs were lysed with DI H2O and analyzed for enzyme activity. 
Twenty microliters of packed cell volume (PCV) RBCs were added to vials 
containing 1 mL of ASNase-LMWP at 20 IU/mL and incubated in a shaking water bath 
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at 37°C. At specified time points, vials were removed and centrifuged to collect RBCs, 
which were subsequently washed three times with R-HBSS before lysing to analyze for 
enzyme activity. For each time point, RBCs incubated in R-HBSS only were used as 
control. 
RBC Encapsulation 
Washed RBCs, 100 uL PCV (packed cell volume), were added to pre-warmed vial 
containing ASNase in R-HBSS (100 U/mL). The RBC-suspended ASNase solutions were 
then incubated in a shaking water bath at 37°C for 30 minutes. The loaded RBCs were 
then washed three times with R-HBSS and measured for ASNase activity. 
Hematological Parameters 
To determine the mean corpuscular volume (MCV), mean corpuscular hemoglobin 
(MCH), mean corpuscular hemoglobin content (MCHC), and relative distribution width 
(% RDW), RBCs resuspended in R-HBSS at 50% hematocrit were analyzed using a 
commercially available veterinary hematology system (Drew Scientific, Dallas, TX). 
Oxygen Dissociation Measurement 
A 10% solution of ASNase-loaded RBCs in Hank’s Buffered Salt Solution (HBSS) 
was washed three times and lysed with distilled water. The resulting hemolysate was 
centrifuged and the supernatant was diluted to 5 ml with a 1:1 mixture of HBSS and 
distilled water.   Dissolved oxygen was measured using a Clark electrode (World 
Precision Instruments, Sarasota, FL) connected to a data acquisition system described by 
Frost et al.46 Oxyhemoglobin was measured using a 37°C thermostated 
spectrophotometer (UV 2501PC, Shimadzu, Columbia, MD) at 540 nm, and change in 
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oxyhemoglobin content of the hemolysate due to decreases in oxygen concentration was 
monitored.   
Scanning Electron Microscopy 
LMWP-ASNase-loaded and sham-loaded (control) RBCs were fixed in 2.5% 
glutaraldehyde in R-HBSS for 1 hour at 4°C and washed three times with R-HBSS. Cells 
underwent dehydration in graded ethanol starting from 50% and finally in absolute 
ethanol. Dehydrated RBCs were washed four times with HMDS (hexamethyldisilazane) 
and air dried over night. After gold sputtering (Polaron E5100) cells were examined by 
scanning electron microscope (1910 Field Emission Scanning Electron Microscope, 
Amray). 
Osmotic Fragility 
LMWP-ASNase- and sham-loaded RBCs were resuspended to 50% hematocrit, and 
20 µl of the RBC suspension was added to 1.0 ml NaCl solutions with osmolality ranging 
from 0 to 300 mOsm/Kg. The solutions were incubated at 37°C for 30 min, centrifuged, 
and the absorbance of each supernatant measured at 540 nm.  The absorbance for 0 
mOsm/Kg solution was taken as 100% hemolysis. The osmolality of each solution was 
measured using a vapor pressure osmometer (Wescor, Logan, UT). 
Statistical Analysis 
All data are expressed as mean ± S.D.  A two-tailed t-test was used in assessing the 




LMWP-Mediated Encapsulation of Proteins into RBC Carriers 
In order to provide physical evidence of the ability of LMWP to transduce proteins 
into RBCs, LMWP was first activated by introducing a thiol moiety to its N-terminus, 
followed by conjugation to a commercial ovalbumin already labeled with the fluorescent 
dye, Alexa Fluor 488. While control native RBCs showed weak autofluorescence from 
hemoglobin excitation (Figure 11A), RBCs incubated with the Alexa Fluor 488-labeled 
ovalbumin also displayed only weak fluorescence on the cell surface, with no observable 
uptake of the labeled protein within the interior of the RBCs (Figure 11B). However, 
after conjugation of labeled ovalbumin with LMWP, significant intracellular fluorescence 
was detected in the cytosol of RBC carriers Figure 11C). 
Optimization of PTD-Mediated ASNase Loading into RBCs 
Results in Figure 11 already provided physical evidence that LMWP was able to 
transport protein molecules into RBCs. By following the similar protocol, we conjugated 
ASNase with LMWP via disulfide linkages as described in Chapter 1. When RBCs were 
incubated with LMWP-ASNase solutions for varying times to determine the kinetics of 
RBC loading, no statistically significant difference was noted within a 10 to 90 minute 
period (see Figure 12). The age of RBCs did not significantly affect ASNase loading as 
long as RBCs were kept in original serum (see Figure 13). When RBCs were incubated 
with LMWP-ASNase conjugates at a total enzyme concentration of 100 IU/mL, a loading 
efficiency of 19.7 ± 3.63 % was observed, with a loading capacity of 19.7 IU of ASNase 
per 100 uL packed cell volume (PCV) of RBCs. 
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RBC Functionality after Encapsulation of LMWP-ASNase 
Since preservation of morphology and physical properties of the RBC through drug 
loading are important, we utilized the SEM method to examine the morphology of the 
ASNase-loaded RBCs obtained by LMWP-mediated encapsulation process. While the 
ASNase-loaded RBCs created using the conventional osmotic rupture-resealing technique 
showed distinctive changes in morphology, RBCs treated with LMWP-ASNase displayed 
morphology identical to that of the control RBCs, with full preservation of the customary 
biconcave shape and no observable deformities (data not shown). In addition when the 
SEM image of ASNase-loaded mouse RBCs prepared by the LMWP-mediated method 
was compared to that of control RBCs, retention of their original biconcave shape made 
them almost indistinguishable from each other (see  Figure 14). 
Also of great significance was that when RBCs loaded with LMWP-ASNase were 
incubated in solutions of decreasing osmolality, the displayed osmotic fragility curve was 
virtually identical to the result of control RBCs. As shown in Figure 15, these RBCs 
displayed “sudden” hemolysis, or a sigmoidal curve, characteristic of normal RBCs. On 
the other hand, had their structure been compromised the resulting osmotic fragility curve 
would have indicated hemolysis of RBCs at all osmolality values, an indicator for a 
heterogeneous population of RBCs as mentioned with glutamate dehydrogease and 
alcohol dehydrogenase encapsulated human (and sheep) RBCs by hypotonic 
dialysis/isotonic resealing method.47 
In addition to confirming the structural integrity of the LMWP-ASNase loaded 
RBCs, we also examined their oxygen transport functionality. As noted with 
conventional methods for protein encapsulation, the loss of intracellular components 
during pore formation or osmotic swelling could result in changes to the normal oxygen-
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binding capabilities of the drug-loaded RBCs. When subjected to varying oxygen 
concentrations, we found that the hemoglobin of the LMWP-ASNase loaded RBCs 
exhibited the characteristic sigmoidal profile indicative of cooperative binding. The Hill 
coefficient and pO50 values for the LMWP-ASNase loaded RBCs were equivalent to 
those of the control RBCs or the previously established values for sheep RBCs (Table 4), 
confirming the presence of the same level of fully functional hemoglobin.  
Additionally, MCV, MCH, MCHC, and RDW showed no statistically significant 
difference between normal and LMWP-ASNase loaded RBCs (Table 3). Comparable 
MCV values further supported results from SEM indicating preservation of RBC 
morphology while MCH values indicated retention of hemoglobin inside RBCs since no 
large pores were created, as observed with electroporation and hypotonic RBC loading 
methods. Furthermore the distribution width (RDW), which is a measure for distribution 
of RBCs with varying sizes, was comparable between two RBC groups suggesting 
homogeneous population of RBCs in terms of size. The onset of hemolysis for majority 
of RBCs at 150 mOsm in osmotic fragility curve also verifies this result. In comparison 
the RDW is wider for hypo-osmotically loaded RBCs. These data demonstrated that cells 
loaded with ASNase using LMWP were virtually identical to normal RBCs with regard 
to both structural and functional properties. 
 
Discussion 
Specific substrate selectivity and unparalleled reaction efficiency bestow proteins 
with the promise of being potent therapeutic agents. Yet, clinical applications of protein 
drugs face two major hurdles; one is their premature degradation and inactivation by 
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endogenous proteases as well as elimination by the reticuloendothelial system (RES), and 
the other is the manifestation of immunological responses and toxic side effects by the 
host immune system towards foreign protein compounds. To overcome such problems, 
the most widely employed strategy is encapsulation of the protein into a soluble and 
biocompatible drug carrier; which can either be a synthetic polymer (e.g. PLGA) or a 
multi-component particulate structure such as liposomes or cells. Among all of these 
carrier systems, RBCs feature a number of distinctive advantages. Not only are RBCs the 
most abundant cells in human body and thus affordable for use in drug encapsulation, but 
they are also completely biocompatible and biodegradable, particularly when autologus 
RBCs are used. In addition, the biconcave disk shape of RBCs endows them with the 
highest surface to volume ratio (1.9 x 104 cm/g) usable for drug encapsulation. Most 
importantly, RBCs possess a lifespan in circulation of approximately 120 days, which is 
significantly longer than any of the currently existing carriers. 
ASNase represents a typical example of these protein therapeutics. Despite its wide 
use in treating ALL, clinical application of ASNase is hindered by the short plasma half-
life and high potential for inducing allergic responses. Hence, ASNase has been 
attempted in almost every method involved in RBC encapsulation. We, therefore, 
selected ASNase to examine the PTD-mediated RBC encapsulation technology, not only 
because of the clinical significance of ASNase, but also a direct comparison of the 
benefits of the new method over existing techniques could be readily attained and 
justified. We also chose the LMWP peptide developed in our laboratory as the 
representative PTD, simply because it possessed similar membrane-translocating activity 
to the most widely studied TAT and yet was proven in animal studies to be neither toxic 
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nor immunogenic.44 Furthermore, to provide direct physical evidence of the utility of the 
new method, we decided to study the LMWP-mediated cell uptake examined via 
confocal fluorescence microscopy, utilizing the Alexa 488 fluorescent dye-labeled 
ovalbumin as the protein marker. As demonstrated in Figure 11, despite a significant 
overlap between the emission wavelengths of Alexa 488 and absorption wavelengths of 
hemoglobin, the green fluorescence from the LMWP-ovalbumin conjugates inside the 
cells were nevertheless quite evident. The horizontal sections along the z-axis (z sections) 
were also taken to ensure that the conjugates were indeed inside the RBCs (data not 
shown). In contrast, without the aid of LMWP, the dye-labeled ovalbumin could not enter 
the cells and only weak fluorescence was observed on the surfaces of RBCs. Based on 
these findings, we were convinced that LMWP would be able to translocate other 
attached proteins such as ASNase into living RBCs. Indeed, by utilizing an optimized 
encapsulation protocol, our results showed that a reasonable ASNase loading efficiency 
(~4%) a RBC loading capacity (8 IU of ASNase per 100 µL of packed RBCs) was 
achieved. Clinically, the dose of ASNase as a sole induction agent in the treatment of 
ALL is about 200 IU/kg body weight.48 Hence, even based on our currently established 
loading protocol, this clinical dosing regimen, which can be translated into a dose of 2.5 
mL of ASNase-loaded RBCs per kg of body weight, is obviously quite achievable. 
In vitro characterization showed there was no leaching or activity decay of the RBC-
encapsulated ASNase over a 3-day incubation period; under which the RBCs remained 
visibly intact. Since LMWP was linked to ASNase via disulfide linkages, it was 
speculated that detachment of LMWP from ASNase via degradation of such bonds by the 
elevated glutathione activity in the cytosol caused the membrane-impermeable ASNase to 
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be trapped inside of the RBC. In addition, it has so far not been established that the PTD-
mediated cell entry is a reversible process. Hence, the permanent entrapment of the 
protein drug inside RBCs could also result from this irreversible translocation 
mechanism. Overall, the absence of leaching and activity decay of the entrapped ASNase 
fulfills one of the essential requirements for the ASNase-loaded RBCs to eventually be 
useful clinically. 
Evidence gathered from our experimental results all point towards the same 
direction; i.e. RBCs after processing by the new encapsulation method remain both 
structurally and functionally intact. The morphology of treated RBCs were indistinctive 
from the untreated cells (see  Figure 14) whereas all of the important cellular parameters 
including MCV, MCH, MCHC, and RDW were all statistically indistinguishable from 
that of untreated RBCs (see Table 3). The most convincing evidence came from the 
oxygen transport capability of the treated RBCs, as ASNase-loaded RBCs displayed 
virtually statistically indistinguishable oxygen transport characteristics, such as the 
measured Hill coefficients and pO50 values, from the untreated, normal RBCs (see Table 
4). 
It should be noted that RBCs treated by any of the existing encapsulation methods, 
either by electroporation or hypotonic dilution, may result in a loss of cellular 
components such as hemoglobin. Several investigators reported that under a carefully 
managed process of hypotonic dialysis and with the aid of a rejuvenating agent during the 
resealing procedure, drug-loaded RBCs could preserve an intact structure and initial 
chemical balance similar to those of native RBCs.49, 50 Nevertheless, in this hypo-osmotic 
drug-loading method, a pore-opening and a resealing step, both involving dialysis, were 
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required. Thus far, the largest protein being encapsulated in RBCs by using this method 
was alcohol oxidase from Pichea pastoria51, which has a molecular weight (675 kDa) 10-
fold larger than that of hemoglobin (65 kDa), the major component of an RBC. Since 
dialysis is an equilibrium process and with such large pores being created on the cell 
membrane, in theory and practice, it is inevitable that some constituents in the cytosol 
such as hemoglobin, glutathione, or cytoskeleton would be leaked out of the RBC. 
Indeed, loss of hemoglobin was observed in RBCs treated with the hypo-osmotic dialysis 
method, as evidenced by a decrease in MCH after resealing.Error! Bookmark not 
defined. As known, aside from the principal activity in oxygen transport, RBCs also 
carry out other important biological functions including energy (ATP)-involved 
metabolic processes as well as scavenging of oxidative stress52. Hence, a loss of 
hemoglobin would not only impair the oxygen transport function of RBCs, but also affect 
their ability to manage oxidative stress. On the other hand, a loss of the cytoskeletal 
constituents would compromise the structural integrity of RBCs, making them prone to 
destruction or recognition by cells in the phagocytic system. 
Osmotic fragility of the treated RBCs has been widely adopted as a measure or 
revealing sign of the membrane integrity after undergoing a drug loading process. 
Numerous reports in the literature indicate changes in osmotic fragility curves after 
loading RBCs with the hypotonic methods.Error! Bookmark not defined.53 Chiarantini 
et al. reported that after hypotonic dialysis followed by hypotonic or isotonic washing, 
RBCs exhibited distinctly different osmotic fragility profiles as well as earlier onset of 
rupture compared to the normal RBCs.53 These findings support the assumption that the 
RBC membranes were considerably weakened during these loading processes. In sharp 
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contrast, our results demonstrated that RBCs being processed through the LMWP-
mediated encapsulation method display a nearly superimposed osmotic fragility profile 
when compared to that of normal RBCs, with both samples showing an identical onset of 
at about 150 mOsm/Kg (see Figure 15). 
These findings further confirm our hypothesis that the PTD-mediated protein 







Figure 11. Confocal microscopy images of control RBCs (row A), RBCs incubated 
with Alexa Fluor 488-labeled ovalbumin (OVA-488; row B), and LMWP-ovalbumin 
(LMWP-OVA-488; row C). First column: fluorescence mode; second column: DIC 
mode; third column: superimposition. Scale bar = 5 µm. (Microscope: Carl Zeiss, 
Jena Germany, LSM 510 META. Objective: 63x, 1.2N. A., Water immersion, Zeiss 
cat. no. 440668. Temperature: 20 °C. Mounting medium: ProLong Gold, Invitrogen, 







Figure 12. Loading kinetics of LMWP-ASNase into mouse RBCs. LMWP-ASNase 
solutions at concentration of 100 U/mL was prepared and loading kinetics into 
mouse RBCs monitored over 90 min period. Statistical analysis indicated no 
significant difference among values for different time points. 
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Figure 13. Effect of mouse RBC age on loading. Comparison of ASNase loading into 
freshly collected RBCs vs. 2-day old RBCs stored as whole blood, or 2-day old but 


















Parameter Control Loaded 
MCV (fL) 58.3 ± 0.4 57.8 ± 0.4 
MCH (pg) 17.3 ± 0.4 16.6 ± 0.3 
MCHC (g/dL) 29.6 ± 0.4 28.7 ± 0.6 
RDW (%) 17.7 ± 0.2 17.4 ± 0.3 
 
Table 3. Hematological parameters of control (sham loaded) and LMWP-ASNase 
loaded mice RBCs. MCV = mean corpuscular volume, MCH = mean corpuscular 














 Figure 14. SEM images of control (sham loaded) and LMWP-ASNase loaded mouse 
RBCs. RBCs were fixed in 2.5% glutaraldehyde in R-HBSS for 1 hour at 4°C. 
Washed cells underwent dehydration in graded ethanol from 50% to absolute 
ethanol. Dehydrated RBCs were washed four times with HMDS 
(hexamethyldisilazane) and air dried overnight. After gold sputtering (Polaron 
E5100) cells were examined by scanning electron microscope (1910 Field Emission 
Scanning Electron Microscope, Amray). 
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Figure 15. Osmotic fragility curves of control (sham loaded) and LMWP-ASNase 



















 Oxygen Dissociation Parameters 
 Control RBCs Loaded RBCs Reference54 
Hill Coefficient 3.15 ± 0.32 3.07 ± 0.34 3.14 ± 0.12 
pO50 (mmHg) 37.44 ± 0.03 38.64 ± 0.02 40.0 ± 1.0 
 
Table 4. Oxygen dissociation parameters of control (sham loaded) and LMWP-
ASNase loaded sheep RBCs are compared to literature values. 
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Chapter 4 
Pharmacokinetics and Therapeutic Efficacy of RBC-Loaded ASNase 
Introduction 
In previous chapters we showed successful encapsulation of LMWP-ASNase into 
RBCs and confirmed that these RBCs are still functionally viable as well as structurally 
comparable to normal RBCs. The ultimate goal of encapsulating LMWP-ASNase into 
RBCs is to improve upon pharmacokinetic properties of ASNase, by maintaining original 
properties of RBCs, and thereby, the therapeutic effect of ASNase. Therefore, additional 
experiments were undertaken to test therapeutic viability and applicability of 
encapsulated ASNase. 
When considering pharmacokinetic properties of ASNase, it is important to keep in 
mind that the circulating half-life of native ASNase is 2.4 - 3.3 (± 0.8) hrs in mice49 
which should significantly increase upon encapsulation into RBCs. At the same time 
when leukemic mice are treated with ASNase-encapsulated RBCs, the life span should 
significantly increase compared to those treated with free- or hypotonically loaded- 
RBCs.  
In order to compare the efficacy of RBC-loaded and native ASNase against leukemia 
it was necessary to come up with a mouse strain and corresponding cell line that will 
respond to ASNase treatment. Horowitz et al mention several murine cell lines that are 
ASNase-sensitive and express low asparagine synthetase activity along with their origin 
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of mouse strain.55 Among those listed the DBA/2 mouse strain with L5178Y cell line was 
chosen for its wide spread application in examining efficacy of various forms of ASNase. 
 
Materials and Methods 
All animal experiments were performed in accordance with the Guide for Laboratory 
Animal Facilities and Care (NIH publication 85-23, revised 1985) and the guidelines of 
the Institutional Animal Care and Use Committee (IACUC) at the University of Utah or 
the University Committee on Use and Care of Animals (UCUCA) at the University of 
Michigan. 
Pharmacokinetics of ASNase Encapsulated in RBCs 
RBCs collected from 6 weeks old DBA/2 mice (Harlan, Indianapolis, IN) were 
treated with LMWP-ASNase conjugates by procedures previously discussed in Chapter 
3. The plasma half-life based on enzymatic activity was calculated after intravenous 
injection of the ASNase-loaded RBCs into the DBA/2 mice. As a control, ASNase was 
encapsulated into RBCs using the conventional hypotonic rupture / resealing method, 
according to a previously established procedure20. In both groups, each individual mouse 
was given 8 units of RBC-encapsulated ASNase (n = 4 per group). Total ASNase activity 
from recipient blood was measured by direct nesslerization. 
Determination of Cytotoxicity in Murine L5178Y Lymphoma Cells by MTT Assay  
Antiproliferative in vitro screening was performed on the murine L5178Y murine 
lymphoma cells (American Type Culture Collection, ATCC; Manassas, VA). 
Cytotoxicity was assessed by MTT assay. The L5178Y cells were suspended into 96-well 
plates at a density of 1 x 10 5 cells/mL in RPMI 1640 (Gibco, Grand Island, NY) 
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supplemented with 10 % FBS. Cells were grown for 24 hrs at 37 °C, 5% CO2, 
humidified, before ASNase treatments. After 72 hours of incubation with ASNase 
formulations, cells were incubated with MTT for an additional 4 hrs. Purple formazan 
product was dissolved in 200 uL DMSO and the corresponding absorbance at 560 nm 
was measured using a microplate reader. The concentrations required in order to inhibit 
cell growth by 50% (IC50) were calculated. 
Optimal ASNase Treatment Time for Tumor Bearing DBA/2 Mice 
L5178Y cells were cultured in RPMI 1640 supplemented with 10% FBS at 37 °C in 
a humidified 5% CO2 environment. Each DBA/2 mouse was given 1 x 106 L5178Y cells 
in 0.2 ml RPMI-1640 media by intraperitoneal injection. On day 1, 2, 3, 4, and 5 after 
tumor implantation a group of mice was selected to receive ASNase (20 U/mouse in 0.1 
mL) by intraperitoneal injection and their survival times recorded. 
Survival of tumor-bearing mice after administration of LMWP-ASNase-loaded 
RBCs 
L5178Y cells were cultured as described above. DBA/2 mice were then given 
intraperitoneal injections of 7 x 105 cells in 0.1 ml HBSS. Five days after tumor 
implantation, mice with narrow bodyweight range were selected and divided into two 
groups: 1) control groups given saline only and 2) RBCs loaded with LMWP-ASNase (n 
= 5 each). Each mouse in group 2 received intravenous injection (tail vein) of LMWP-
ASNase loaded RBCs equivalent to 8 units of free ASNase. The subsequent survival of 
the tumor-bearing mice was monitored. 
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Statistical Analysis 
 All data are expressed as mean ± S.D. The log-rank test was used in the survival 
study of the tumor-bearing mice. A p-value of less than 0.05 was considered significant. 
 
Results 
Prolonged Circulation Half-Life of ASNase Encapsulated in RBCs 
Since RBCs loaded with LMWP-ASNase closely resembled normal RBCs in 
functionality and retained physical properties, we hypothesized that encapsulated ASNase 
would inherit the same, extended circulation half-life of normal RBCs. To test this 
hypothesis, we injected DBA/2 mice with LWMP-ASNase loaded RBCs by tail vein, and 
the circulation half-life of ASNase was determined from the linear portion of the 
elimination phase. For comparison, we also prepared ASNase-loaded RBCs with 
equivalent enzyme concentrations using the conventional hypo-osmotic rupture/resealing 
technique. While both types of RBCs showed a biphasic disappearance of enzymatic 
activity over time, ASNase loaded into the RBCs by LMWP-mediated procedure 
displayed a significantly longer circulation half-life (4.5 ± 0.5 days) than that of ASNase 
loaded  into RBCs by hypo‐osmotic rupture / resealing method (2.4 + 0.7 days), as 
depicted  in Figure 16,  or  the  free ASNase which had  circulating half‐life of 3.3 hrs 
(data not shown). 
Verification of Murine L5178Y Leukemia Cell Line Sensitivity to ASNase 
Prior to initiating an efficacy study of ASNase in mice model, we wanted to verify 
that the leukemia cell line to be used, L5178Y, was indeed sensitive to ASNase treatment 
as this cell line has been known to become insensitive to ASNase treatment.56 When 
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these cells were incubated with comparable dose of either native or LMWP-conjugated 
ASNase for 72 hrs, and cell viability measured by MTT assay, the IC50 was determined to 
be 9.74 IU/mL for native and 1.95 IU/mL for LMWP-conjugated ASNase (see Figure 17) 
indicating not only that these cells were sensitive to ASNase treatment but also that the 
conjugation of LMWP increased cytotoxicity of ASNase. 
Therapeutic efficacy of RBC-encapsulated ASNase 
Upon verification of sensitivity of L5178Y cells to ASNase, the therapeutic efficacy 
was examined. We injected RBCs loaded with LMWP-ASNase into L5178Y lymphoma-
bearing DBA/2 mice to examine the therapeutic efficacy of the encapsulated enzyme. On 
day five after tumor injection and when symptoms became apparent, 8 IU of RBC-loaded 
ASNase were intravenously injected. Compared to control animals which received saline 
injections, the animals treated with LMWP-ASNase loaded RBCs showed a significant 
increase in mean survival time, almost a 44% increase, from 10.0 ± 1.4 days to 14.4 ± 2.3 
days, as shown in Figure 18. 
 
Discussion 
One of the proofs of the benefits of the LMWP-mediated cell encapsulation method 
stemmed from the in vivo pharmacokinetic study of the plasma half-life of the ASNase-
loaded RBCs. For comparison, RBCs loaded with ASNase via a hypotonic method were 
used as a control. Consistent with the findings by other investigators23, 21, 49 the hypotonic 
method resulted in changes in morphology and surface structures of many of the treated 
RBCs and, as a consequence, significantly shortened the circulating half-lives of such 
cells. An overall half-life of approximately 2.4 days was found for RBCs treated with the 
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hypotonic method whereas, in contrast, RBCs treated with the LMWP mediated method 
exhibited significantly prolonged plasma half-life of 4.5 days; almost double the value for 
the hypotonic treated RBCs (see Figure 16). However, we believe that there is room for 
improvement because biological carriers like RBCs require more strict measures of 
handling precautions57, as evidenced by the fact that the reported half-lives of 
manipulated RBC in rodents show variable results19, 20, Error! Bookmark not defined., 
58. Therefore, upon optimization of the RBC encapsulation method via PTD peptide, it is 
expected that the half-life of enzyme-loaded RBCs will increase compared to the results 
we have obtained from our preliminary study. 
For the ASNase-loaded RBCs to function desirably, another essential requirement is 
that the entrapped drug must be able to retain its original therapeutic capability. To 
validate this criterion, we tested the therapeutic functions of the ASNase-loaded RBCs 
against a L5178Y lymphoma tumor-bearing DBA/2 mouse model. As can be seen in 
Figure 18, administration of ASNase-loaded RBCs was able to considerably increase the 
median survival time of the mice (14.4 days), when compared to the median survival time 
of 10 days observed from the saline-injected control group; an enhancement of the 
survival time by 44%. It should be quite easy to assess the prowess of the proposed RBC-
encapsulation technology in ASNase therapy, after comparing our results with findings 
by others under similar in vivo conditions. As reported, a nearly 16.7% enhancement in 
survival time over the control was observed by other investigators following intravenous 
injection of 8 IU of free ASNase to L5178Y tumor bearing mice.59 Previously, TAT-
ASNase was investigated for potential application for targeted therapy of ALL60,61. The 
same tumor model (L5178Y/ DBA/2) showed that the mean survival time of L5178Y cell 
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implanted DBA/2 mice treated with free ASNase showed no improvement with respect to 
an untreated control group61. It is also noteworthy that Alpar and Lewis investigated 
ASNase-loaded in RBCs, which reports impressively longer survival in treated animals.62 
However, in that work, different tumor cell lines and animal models (6C3HED cell lines, 
C3H mice) were used. The median survival time of the mice in the untreated control 
group was about 18 days whereas L5178Y implanted DBA/2 mice in our study as well as 
previous studies61 showed only 10 days, suggesting the tumor burden in DBA/2 strikes 
animals more quickly and severely than the C3H mice. The difference is further 
evidenced by in vitro doubling time of the two cell lines — L5178Y divides more rapidly 
than 6C3HED cells (data not shown). A more extensive animal investigation designed to 
further demonstrate the long-term benefits of this new approach in ASNase therapy, such 
as the alleviation of ASNase-induced toxic and immunologic responses, is currently in 








Figure 16. Time profile of ASNase activity in blood in DBA/2 mice (n=4). LMWP-
ASNase loaded RBCs (8 IU ASNase per mouse; blue diamond) and ASNase-loaded 
RBC ghosts (8 IU ASNase per mouse; red square) were given via intravenous 
injection through tail vein. ASNase activities in whole blood specimens were 








Figure 17. Cytotoxicity of native ASNase and LMWP-ASNase. L5178Y cells were 













Figure 18. Kaplan-Meier survival curve for DBA/2mice bearing L5178Y lymphoma 
cells. RBC encapsulated LMWP-ASNase (8 IU ASNase per mouse; solid line) or 
saline (dotted line) were given on day 5 after tumor implantation when symptom 




In conclusion, an innovative method for encapsulation of therapeutically active 
ASNase into functionally intact RBCs was developed toward enhanced ASNase therapy 
for ALL. Because of the non-invasive nature of PTD-mediated cell entry, our results 
showed that the structural and functional integrity of both the loaded ASNase and 
processed RBCs were completely reserved. RBCs treated by this encapsulation method 
not only exhibited a long circulating half-life similar to that of untreated RBCs, but also 
displayed enhanced therapeutic effects of the entrapped protein drug, presumably via 
protection of the drug by RBCs from possible proteolytic degradation and phagocytic 
clearance. It should be noted that full preservation of both structure and function of the 
treated RBCs is of great clinical significance because theoretically this would provide the 
flexibility of replacing an unrestrictive amount of blood (or RBCs) from the patient with 
drug-loaded RBCs, should situations warrant such for clinical management. 
Furthermore, for second remission treatment of ALL the pegaspargase did not show 
advantage over native ASNase. However, with RBC encapsulated ASNase, with the RBC 
membrane acting as a shield to mask the enzyme from the circulation, we can expect a 
reduced immunogenic effect, which would allow use of ASNase in patients with 
sensitivity to the enzyme. 
Based on this simple encapsulation method, a plasmapheresis-type of blood auto-
transfusion system is currently being designed in our lab in which RBCs are separated 
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from whole blood, processed through the LMWP-ASNase loading process, merged back 
with other blood components, and finally returned to the patient for in situ drug therapy 
for ALL. 
Overall, this universal method of encapsulation may also be applied to several other 
protein drugs. Applications of this technology for the treatment of cocaine overdose, 
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